Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration
Figure 2
Distribution of visual acuity change from baseline based on visual acuity status at month 3 among pooled ranibizumab-treated patients by clinical trial. aAll visual acuity changes are compared with baseline. For ease of interpretation, all percentages are rounded to the nearest whole number.
